Cabot Corporation
NYSE:CBTChemicals - Specialty
+$0.96 today
- Market cap
- $3.80B
- Beta
- 0.83
- P/E (TTM)
- 16.3
- EPS (TTM)
- $5.48
- Dividend yield
- 2.04%
Volume 0.53M
Average 0.43M
CBT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cabot CorporationNYSE: CBT
Cash & Equivalents · Q3 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 4.6% from a year ago
Cash & equivalents stood at $250M at the end of Q3 FY2026, up 4.6% from a year earlier and down 0.8% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.
Context
- Cash & equivalents amounted to 6.3% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +4.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 258M USD
- Year-over-year change
- +15.7%
- 4-year CAGR
- +11.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 258M | +15.7% |
| FY2024 | 2024-09-30 | 223M | -6.3% |
| FY2023 | 2023-09-30 | 238M | +15.5% |
| FY2022 | 2022-09-30 | 206M | +22.6% |
| FY2021 | 2021-09-30 | 168M | — |
Cash & Equivalents vs competitors
How CBT compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4.6% is the 5th highest of 11, against a peer median of -10.3%.
- Cash & equivalents amounts to 6.3% of total assets for CBT, versus a peer median of 3.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | ZAR 42.96B ZAR | +4.6% | -7.3% | 11.9% | |
| Jun 2026 | $1.36B USD | +16.3% | -5.7% | 6.4% | |
| Sep 2026 | $445.7M USD | +0.0% | -7.3% | 7.5% | |
| Jun 2026 | $382.45M USD | -21.4% | -20.7% | 5.3% | |
| Jun 2026 | $250M USD | +4.6% | +7.8% | 6.3% | |
| Aug 2026 | $97.23M USD | -20.6% | +10.3% | 1.8% | |
| Jun 2026 | $82.78M USD | -41.2% | +37.0% | 2.6% | |
| Aug 2026 | $70.61M USD | +21.5% | +13.6% | 14.3% | |
| Jun 2026 | $40.69M USD | +52.9% | +130.4% | 1.0% | |
| Jun 2026 | $31.02M USD | -45.3% | +20.4% | 1.3% | |
| Sep 2026 | $7.1M USD | -31.8% | -19.7% | 0.7% | |
| Peer median (excluding CBT) | — | -10.3% | +2.3% | 3.9% | |
Competitors are the stored peer set for CBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 168M | 206M | 238M | 223M | 258M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 645M | 836M | 695M | 733M | 671M |
| Inventory | 523M | 664M | 585M | 552M | 504M |
| Other Current Assets | 0 | 0 | 108M | 0 | 106M |
| Total Current Assets | 1.43B | 1.82B | 1.63B | 1.61B | 1.54B |
| Property, Plant & Equipment (Net) | 1.38B | 1.27B | 1.41B | 1.53B | 1.71B |
| Goodwill | 140M | 129M | 134M | 133M | 134M |
| Intangible Assets | 100M | 63M | 60M | 53M | 55M |
| Long-term Investments | 40M | 20M | 20M | 23M | 16M |
| Tax Assets | 53M | 45M | 180M | 216M | 180M |
| Other Non-current Assets | 172M | 178M | 172M | 172M | 180M |
| Total Non-current Assets | 1.88B | 1.71B | 1.98B | 2.13B | 2.28B |
| Total Assets | 3.31B | 3.53B | 3.6B | 3.74B | 3.82B |
| Account Payables | 480M | 533M | 438M | 495M | 459M |
| Short-term Debt | 445M | 354M | 182M | 67M | 274M |
| Tax Payables | 35M | 44M | 40M | 43M | 35M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 75M | 66M | 55M | 167M | 77M |
| Total Current Liabilities | 1.15B | 1.11B | 822M | 772M | 957M |
| Long-term Debt | 717M | 1.09B | 1.09B | 1.15B | 856M |
| Deferred Tax Liabilities | 73M | 65M | 50M | 42M | 39M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 195M | 151M | 147M | 69M | 173M |
| Total Non-current Liabilities | 1.07B | 1.39B | 1.38B | 1.37B | 1.15B |
| Total Liabilities | 2.22B | 2.49B | 2.2B | 2.15B | 2.11B |
| Common Stock | 57M | 56M | 55M | 54M | 53M |
| Retained Earnings | 1.16B | 1.28B | 1.57B | 1.73B | 1.84B |
| Accumulated OCI | (289M) | (439M) | (362M) | (360M) | (335M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 143M | 134M | 143M | 165M | 155M |
| Total Equity | 1.09B | 1.03B | 1.41B | 1.59B | 1.71B |
| Total Debt | 1.25B | 1.53B | 1.36B | 1.33B | 1.22B |
| Net Debt | 1.08B | 1.32B | 1.12B | 1.11B | 957M |
Cabot Corporation
NYSE:CBT
Intrinsic Alpha fair value
Locked
Current Price
$74.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.